CATH Classification
| Level | CATH Code | Description |
|---|---|---|
|
3 | Alpha Beta |
|
3.30 | 2-Layer Sandwich |
|
3.30.200 | Phosphorylase Kinase; domain 1 |
|
3.30.200.20 | Phosphorylase Kinase; domain 1 |
Domain Context
CATH Clusters
| Superfamily | Phosphorylase Kinase; domain 1 |
| Functional Family | Hepatocyte growth factor receptor |
Enzyme Information
| 2.7.10.1 |
Receptor protein-tyrosine kinase.
based on mapping to UniProt P08581
ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.
-!- The receptor protein-tyrosine kinases, which can be defined as having a transmembrane domain, are a large and diverse multigene family found only in metazoans. -!- In the human genome, 58 receptor-type protein-tyrosine kinases have been identified and these are distributed into 20 subfamilies. -!- Formerly EC 2.7.1.112.
|
UniProtKB Entries (1)
| P08581 |
MET_HUMAN
Homo sapiens
Hepatocyte growth factor receptor
|
PDB Structure
| PDB | 4EEV |
| External Links | |
| Method | X-RAY DIFFRACTION |
| Organism | |
| Primary Citation |
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.
Invest New Drugs
|
